Urine cfRNA in Bladder Cancer: Detection and Treatment Response
Urine cfRNA in Bladder Cancer: Detection and Treatment Response Oncodaily
Онкология
🎗️Лента новостей
Онкология
RWJBarnabas, Hackensack Meridian Health cited by Becker’s for oncology programs - ROI-NJ
RWJBarnabas, Hackensack Meridian Health cited by Becker’s for oncology programs ROI-NJ
🎗️
Онкология
New Prostate Cancer Foundation Cardiovascular Risk Framework for Patients Receiving Hormone Therapy Published in JCO Oncology Practice
New Prostate Cancer Foundation Cardiovascular Risk Framework for Patients Receiving Hormone Therapy Published in JCO Oncology Practice Business Wire
🎗️
Онкология
Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer Business Wire
Онкология
Cancer Today’s Fall 2026 Issue: Activity-based Groups for Survivors and More | Blog | AACR
Cancer Today’s Fall 2026 Issue: Activity-based Groups for Survivors and More | Blog | AACR American Association for Cancer Research
🎗️
Онкология
N-Power Medicine and New York Cancer & Blood Specialists Partner to Scale Prospective External Control Arms (ProECA) in Community Oncology
N-Power Medicine and New York Cancer & Blood Specialists Partner to Scale Prospective External Control Arms (ProECA) in Community Oncology Business Wire
Онкология
Новые перспективы в лечении трижды негативного рака молочной железы с помощью иммунотерапии.
Новые перспективы в лечении трижды негативного рака молочной железы с помощью иммунотерапии. Vietnam.vn
Онкология
RAS Research: From Undruggable to New Treatments
RAS Research: From Undruggable to New Treatments National Cancer Institute (.gov)
Онкология
Как работает лечение рака вакцинами и почему их не нужно бояться
Как работает лечение рака вакцинами и почему их не нужно бояться ФедералПресс
Онкология
Stanford spent more than 20 years developing a blood-cancer transplant therapy; its first commercial pati
Stanford spent more than 20 years developing a blood-cancer transplant therapy; its first commercial pati The Times of India